



IGC Readies Line of Medical Dispensary Products Targeting Alzheimer's Disease Based on Novel Data

Drug Candidate for Alzheimer's Shows Promise by Inhibiting A β Aggregation without Neuron Damage

Bethesda, MD. September 18, 2017– India Globalization Capital, Inc. (NYSE-MKT: IGC) provides an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer's disease model, showing that at varying concentrations of THC, the aggregation of A β protein decreases by as much as 40%.

“As Alzheimer's progresses, synaptic dysfunction and the death of neurons lead to memory loss. These study results, when combined with the earlier reported data that shows IGC-AD1 reduces A β 40 and A β 42 production by as much as 50%, and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease,” states IGC's CEO Ram Mukunda.

It is believed that a primary cause of AD is the buildup of senile plaque composed of amyloid beta peptides (A β plaque) in the cerebral cortex and hippocampus. The key pathogenic event in the onset of AD is A β peptide monomers aggregating into prefibrillar oligomers (dimers, trimers, tetramers and oligomers). As AD progresses A β oligomers directly cause synaptic dysfunction and the death of neurons, consequently leading to a loss of memory.

“A drug that (i) decreases production of A β , (ii) inhibits A β aggregation into oligomers, (iii) is not toxic to neurons, and (iv) does not cause inebriation (high), could be a powerful weapon against AD and the prevention of AD. In vitro, our product demonstrates these critical factors and we are pursuing a patent filing that protects this therapy.

AD starts 20 to 25 years before symptoms like memory loss are manifested. Statistically, there is an almost 50% chance of individuals over 80 years contracting AD and over 65% of AD patients are women. Based on the findings of these studies, our plan is two-fold. First, we will position IGC-AD1 as a drug that can be used both as a treatment for AD, and as a prophylactic treatment for the prevention of AD. Second, we will commercialize a supplement version to be sold as a medical dispensary product. This will allow our team to work through the FDA approval process for IGC-AD1, while securing market share in the medical dispensary segment. This is a very exciting time for all our

shareholders and I look forward to providing updates on our progress in combatting this global disease,” concludes IGC’s CEO Ram Mukunda.

The summary in vitro data indicates that between 2.5nM and 25nM THC concentration, the formation of A β 1-42 trimers and tetramers in N2aAPP cells are reduced by up to 40% as determined by both fluorescence and immuno blotting assays. Dr. Chuanhai Cao, IGC’s Senior Advisor and Associate Professor of Pharmaceutical Sciences at USF’s College of Pharmacy conducted the studies.

About Alzheimer’s Disease

Alzheimer’s Disease (AD) is a form of dementia. It is known as America’s most expensive disease, with an estimated cost to the U.S. economy of \$236 billion. AD currently affects more than 5.3 million Americans and over 65% of AD patients are women. Over the next 20 years, the number of those afflicted with the disease is expected to double. The forecast is staggering, considering that to date, no effective cure has been found.

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.

For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements

Please see forward looking statements as discussed in detail in IGC's Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact:

Claudia Grimaldi
301-983-0998